ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
AzurRx BioPharma Inc

AzurRx BioPharma Inc (AZRX)

3.45
0.00
(0.00%)
At close: 07 January 8:00AM
3.45
0.00
( 0.00% )

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.45
Bid
3.41
Offer
3.51
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
3.45
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
13,500,000
Dividend Yield
-
PE Ratio
-2.48
Earnings Per Share (EPS)
-1.19
Revenue
-
Net Profit
-16.1M

About AzurRx BioPharma Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-

AZRX Latest News

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to...

AzurRx BioPharma Announces Reverse Stock Split

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the...

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022...

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...

AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

AZRX - Frequently Asked Questions (FAQ)

What is the current AzurRx BioPharma share price?
The current share price of AzurRx BioPharma is US$ 3.45
How many AzurRx BioPharma shares are in issue?
AzurRx BioPharma has 13,500,000 shares in issue
What is the market cap of AzurRx BioPharma?
The market capitalisation of AzurRx BioPharma is USD 46.58M
What is the 1 year trading range for AzurRx BioPharma share price?
AzurRx BioPharma has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of AzurRx BioPharma?
The price to earnings ratio of AzurRx BioPharma is -2.48
What is the reporting currency for AzurRx BioPharma?
AzurRx BioPharma reports financial results in USD
What is the latest annual profit for AzurRx BioPharma?
The latest annual profit of AzurRx BioPharma is USD -16.1M
What is the registered address of AzurRx BioPharma?
The registered address for AzurRx BioPharma is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the AzurRx BioPharma website address?
The website address for AzurRx BioPharma is www.enterothera.com
Which industry sector does AzurRx BioPharma operate in?
AzurRx BioPharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MSAIMultiSensor AI Holdings Inc
US$ 2.80
(40.00%)
2.52M
MCVTMill City Ventures III Ltd
US$ 3.10
(37.17%)
85.45k
XTIAXTI Aerospace Inc
US$ 0.1115
(26.70%)
362.56M
QRTEBQurate Retail Inc
US$ 3.13
(22.27%)
103
NARIInari Medical Inc
US$ 78.80
(21.23%)
4.7M
AMSTAmesite Inc
US$ 3.38
(-16.54%)
59.87k
GDTCCytoMed Therapeutics Ltd
US$ 2.89
(-15.74%)
61.92k
ENVBEnveric Biosciences Inc
US$ 0.3568
(-15.55%)
377.21k
ACXPAcurx Pharmaceuticals Inc
US$ 0.924
(-15.23%)
165.97k
SLRNACELYRIN Inc
US$ 2.98
(-14.61%)
505.98k
XTIAXTI Aerospace Inc
US$ 0.1115
(26.70%)
362.56M
SVMHSRIVARU Holding Ltd
US$ 0.0519
(12.10%)
29.45M
CRKNCrown Electrokinetics Corporation
US$ 0.1401
(5.34%)
25.17M
CEROCERo Therapeutics Holdings Inc
US$ 0.0489
(15.60%)
17.02M
CDTConduit Pharmaceuticals Inc
US$ 0.0827
(14.38%)
16.62M

Discussion

View Full Feed
badog badog 25 seconds ago
I never had the link. I wouldn't open a link by a person who posted for the first time. Homebrew may have it.
Badog
ERHE
Investor2014 Investor2014 44 seconds ago
Yes EMA approval may result in a limited label FDA conditional approval requiring a confirmatory trial that shows dose dependence, is longer and larger with diverse ethnicity.
AVXL
ThunderousSeer8 ThunderousSeer8 2 minutes ago
Yes. I am invested here and in many other markets. I've been here since April of this year. These guys just can't cut it, man. You can see it in the frequency of their posts. They live for this, they absolutely think highly of themselves even though the frequency at which they post shows they haven'
RDAR
longrider51 longrider51 2 minutes ago
Recall and consider the source, right?
This article appeared on National Review (Online) on January 24, 2021.
Note National Review is distinctly a politically right oriented outfit ..
https://mediabiasfactcheck.com/national-review/ .
PickStocks PickStocks 2 minutes ago
Tell everyone again how you are a crypto guru.....did you take advice from the hawk Tuah girl...
COOP
SSKILLZ1 SSKILLZ1 2 minutes ago
OPTT Was the best performing stock pick today picked by NSOMNIYAK and the Best Top Pick was OPTT picked by NSOMNIYAK. hope this helps.
OPTT
XMaster2023 XMaster2023 4 minutes ago
You missed the point EX. The demand for C-19 vaccines is diminishing. Why is Merck spending 500 mil to increase capacity?
Perhaps they want to help out their Chinese competitors?
Perhaps they need more Vaccine capacity?
Perhaps they already have a deal cut with NWBO and it i
NWBO
Juststoppingby Juststoppingby 5 minutes ago
It looks like they still need to comply with rule 15c2-11, which took effect not too long ago.

How to Become Quoted on the Pink Market
To be eligible for quotations, companies must:
1. Comply with the requirements of Securities Exchange Act Rule 15c2-11
2. Make cu
CRTG
janice shell janice shell 5 minutes ago
Neither the NIH or the FDA is a scam. Do yourself a favor, and don't get sucked into conspiracy theories.
cottonmather cottonmather 5 minutes ago
Tidbits: USS Harry Truman experienced a largescale attack of drones and missiles. No direct hits. Trump continues backing off his promises - tarrifs falling to the side.
freecs freecs 6 minutes ago
Lol yikes. Speechifying.
RDAR
Pickme2 Pickme2 7 minutes ago
Ok Ones...another foolish remark as always
ATMH
cottonmather cottonmather 7 minutes ago
Tidbits: USS Harry Truman experienced a largescale attack of drones and missiles. No direct hits. Trump continues backing off his promises - tarrifs falling to the side.
Jimmy Joe Jimmy Joe 7 minutes ago
It's all relative.
DBMM
janice shell janice shell 8 minutes ago
What on earth are "real nobel prize clinical trials with the fda"???
bbotcs bbotcs 9 minutes ago
al44: That article was made to order for you!
SSKILLZ1 SSKILLZ1 9 minutes ago
SSKMP Managed Index (As Of 1/6/25)

Daily Performance
-0.45%

YTD Performance
+0.10%

Overall Performance
+519.55% (Including Options Trading +383.53%)
Tony53711 Tony53711 9 minutes ago
Zivo blew opportunities during the pandemic to find a partner with funding to quickly develop a therapeutic. Didn’t they learn their lesson? We were told during the last test it was funded by a partner and agreements would be signed pending results. Results were positive and we are going on how many
ZIVO
Techroemancer Techroemancer 10 minutes ago
Just for the fun of it, why not?

If we have major news and updates - .15+
If we have lots of news but nothing major - .07
If we have a little news but nothing major - .03
If we have no news - .008

All guessing here
MGON
Jimmy Joe Jimmy Joe 10 minutes ago
Looks like a big block position is being sold.

Total NONSENSE. What big block you are talking about~?
Only 459K total volume dude.
Big sells would be 100 million total volume.
Big covering would be 100s of millions or billions of shares in a single day.
DBMM
4C 4C 12 minutes ago
Has JHB laid down the law to Dalton?

We know Dalton's wife has been unwell, and there were rumors on LinkedIn that he himself might have some kind of health issue, we also know they've relocated to Georgia and it's highly likely that they have moved in with Chiatra and JHB.
UNVC
WojD40 WojD40 12 minutes ago
But aren’t we thinking that a majority of the remaining short position is being held by people who also have warrants? I’m a little confused by this. Why wouldn’t you cover at sub $0.30 when you sold short at $0.75-$1.00.
NWBO

Your Recent History

Delayed Upgrade Clock